G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

Abstract The treatment of non-small cell lung cancer (NSCLC) patients has significantly improved with recent therapeutic strategies; however, many patients still do not benefit from them.As a result, new treatment approaches are urgently needed.In this study, we evaluated the antitumor efficacy of co-targeting G9a and DNMT1 enzymes and its potentia

read more